Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease | Journal of the International Neuropsychological Society | Cambridge Core (original) (raw)

Abstract

Patients with Alzheimer's Disease (AD) who have reached a stage of moderate to severe dementia are capable of completing a restricted range of cognitive tests and performing a limited range of activities of daily living (ADL). As part of an initiative to develop instruments to evaluate AD, we analyzed data describing the performance of a large number of ADL and scores on cognitive and global assessment measures in a cohort of patients with AD with moderate to severe cognitive impairment, defined as a Mini-Mental State Examination score ranging from 0–15 (out of 30). From the large pool of ADL, 19 met criteria of applicability, reliability, good scaling, concordant validity, and sensitivity to detect change in performance over 6–12 months. A total score derived from these 19 ADL ratings, comprising a scale termed the Alzheimer Disease Cooperative Study ADL-sev, correlated strongly with measures of cognition and of global dementia severity. Patients with moderate to severe AD showed a decline on the ADL-sev and cognitive measures over 6 and 12 months, consistent with the progression of AD. Detailed evaluation of ADL may provide a useful index to evaluate patients with moderate to severe AD and may complement cognitive assessment, especially for characterizing change in interventional or therapeutic studies. (JINS, 2005, 11, 446–453.)

References

Berg, L.(1988).Clinical Dementia Rating (CDR).Psychopharmacology Bulletin,24,637–639.Google Scholar

Brane, G.,Gottfries, G.C., &Winblad, B.(2001).The Gottfries-Brane-Steen scale: Validity, reliability and application in anti-dementia drug trials.Dementia and Geriatric Cognitive Disorders,12,1–14.Google Scholar

Cohen, J.(1960).A coefficient of agreement for nominal scales.Educational Psychological Measures,20,37–46.CrossRef Google Scholar

DeJong, R.,Osterlund, O.W., &Roy, G.W.(1989).Measurement of quality of life changes in patients with Alzheimer's disease.Clinical Therapy,11,545–554.Google Scholar

Doody, R.,Wirth, Y.,Schmitt, F., &Mobius, H.J.(2004).Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.Dementia and Geriatric Cognitive Disorders,18,227–232.Google Scholar

Feinstein, A.R.,Josephy, B.R., &Wells, C.K.(1986).Scientific and clinical problems in indexes of functional disability.Annals of Internal Medicine,105,413–420.Google Scholar

Ferris, S.E.,Mackell, J.A.,Mohs, R.,Schneider, L.S.,Galasko, D.,Whitehouse, P.,Schmitt, F.A.,Sano, M.,Thomas, R.G.,Ernesto, C.,Grundman, M.,Schafer, K.,Thal, L.J., &Alzheimer's Disease Cooperative Study(1997).A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: Overview and general results.Alzheimer Disease and Associated Disorders,11(suppl 2),S1–S12.Google Scholar

Folstein, M.F.,Folstein, S.E., &McHugh, P.H.(1975).“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician.Journal of Psychiatric Research,12,189–198.CrossRef Google Scholar

Galasko, D.,Bennett, D.,Sano, M.,Ernesto, C.,Thomas, R.,Grundman, M.,Ferris, S.H., &Alzheimer's Disease Cooperative Study(1997).An inventory to assess activities of daily living for clinical trials in Alzheimer's disease.Alzheimer Disease and Associated Disorders,11(suppl 2),S33–S39.CrossRef Google Scholar

Gelinas, I.,Gauthier, L.,McIntyre, M., &Gauthier, S.(1999).Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia.American Journal of Occupational Therapy,53,471–481.CrossRef Google Scholar

Katz, S.,Ford, A.B., &Moskowitz, R.W.(1963).The index of ADL: A standardized measure of biological and psychosocial function.Journal of the American Medical Association,185,914–919.Google Scholar

Lawton, M.P. &Brody, E.M.(1969).Assessment of older people: Self-maintaining and instrumental activities of daily living.Gerontologist,9,179–186.Google Scholar

Panisset, M.,Roudier, M.,Saxton, J., &Boller, F.(1994).Severe impairment battery. A neuropsychological test for severely demented patients.Archives of Neurology,51,41–45.Google Scholar

Reisberg, B.,Doody, R.,Stoffler, A.,Schmitt, F.,Ferris, S.,Mobius, H.J., &Memantine Study Group(2003).Memantine in moderate-to-severe Alzheimer's disease.New England Journal of Medicine,348,1333–1341.Google Scholar

Reisberg, B.,Ferris, S.H.,de Leon, M.J., &Crook, T.(1988).The Global Deterioration Scale (GDS).Psychopharmacology Bulletin,24,661–663.Google Scholar

Reisberg, B.,Finkel, S.,Overall, J.,Schmidt-Gollas, N.,Kanowski, S.,Lehfeld, H.,Hulla, F.,Sclan, S.G.,Wilms, H.U.,Heininger, K.,Hindmarch, I.,Stemmler, M.,Poon, L.,Kluger, A.,Cooler, C.,Bergener, M.,Hugonot-Diener, L.,Robert, P.H.,Antipolis, S., &Erzigkeit, H.(2001).The Alzheimer's disease activities of daily living international scale (ADL-IS).International Psychogeriatrics,13,163–181.CrossRef Google Scholar

Rosen, W.G.,Mohs, R.C., &Davis, K.L.(1984).A new rating scale for Alzheimer's disease.American Journal of Psychiatry,141,1356–1364..Journal of the American Geriatric Society,39,339–347.Google Scholar

Streiner, D.L. &Norman, G.R.(1995).Health measurement scales: A practical guide to their development and use(2nd ed.).Oxford:Oxford Medical Publications.

Tariot, P.N.,Farlow, M.R.,Grossberg, G.T.,Graham, S.M.,McDonald, S.,Gergel, I., &Memantine Study Group(2004).Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial.Journal of the American Medical Association,291,317–324.CrossRef Google Scholar